Interventional Glaucoma

In a small study, a combination over-the-counter supplement with antioxidant and mitoprotective properties significantly reversed mitochondrial dysfunction.

Results from MERCURY-1, a 12-month phase III pivotal trial, show that once daily treatment with fixed-dose combination netarsudil 0.02%/latanoprost 0.005% (Aerie Pharmaceuticals) is safe and provided significantly greater IOP-lowering than either of its components throughout follow-up.

Know the patient’s family history of glaucoma, and conduct a comprehensive exam before LASIK procedure. It is crucial to monitor the patient after surgery; watch for interfact cysts, loose flaps, and pressure-induced interlamellar stromal keratitis.

Jonathan S. Myers, MD, reports that intraocular drug delivery systems could help solve the problem of poor adherence in patients taking glaucoma medications. Implanted in the eye, the systems would allow for glaucoma drugs to gradually dissolve or elute medication.

Compared with SLT, PSLT appears to offer some advantages, such as a shorter duration of treatment and more comfort for patients.

Steven Vold, MD, reports that toric IOLs provide an accurate, safe, and convenient way to correct astigmatism and uncorrected distance vision for glaucoma patients, while patients wanting presbyopic correction have IOL options to fit a range of visual needs.

Until now, surgery has been considered a second-line treatment after medication and lasers because of the risks associated with trabeculectomy and tube shunts. Now ophthalmologists can draw from a larger surgical tool chest, explains Iqbal Ike K. Ahmed, MD.

Advances in phacoemulsification are creating new opportunities for glaucoma surgery, especially in developing countries, according to Alan S. Crandall, MD.

One laboratory is at work on new devices that use visual stimuli to prompt retinal ganglion cells to regenerate, while two other researchers describe techniques through which virtual reality might diagnose the disease more accurately than standard automated perimetry.

One laboratory is at work on new devices that use visual stimuli to prompt retinal ganglion cells to regenerate, while two other researchers describe techniques through which virtual reality might diagnose the disease more accurately than standard automated perimetry.

In addition to making use of MIGS, interventional glaucoma might utilize other novel drainage devices and sustained drug-delivery devices and be combined with cataract surgery. This approach is more proactive, aims at lower IOP, lowers risk and addresses adherence, said Iqbal Ike K. Ahmed, MD.

Glaucoma 360, a three-day event being held here by the Glaucoma Research Foundation (GRF), will move from its "Celebrate" phase with Annual Gala on Thursday into its "Innovate" phase with the New Horizons Forum set for today. This event is a full day of presentations, panels, and discussions featuring leaders from start-up companies, industry executives, ophthalmic experts, venture capitalists, and the FDA.

Glaucoma 360, a three-day event organized by the Glaucoma Research Foundation (GRF) will move into its final day on Saturday with the Glaucoma Symposium. The focus will shift from "Innovate" to "Educate." Two continuing medical education sessions are-one for ophthalmologists in the morning and another for optometrists in the afternoon.

Although there are no scientifically proven ways to prevent glaucoma, healthy habits–such as moderate exercise, regular visual check-ups, and eating green, leafy vegetables–represent a good starting point for a prevention strategy.

Investigations of the biomechanical changes in the optic nerve head may eventually lead to improvements in therapies for patients with glaucoma.

A portable device for detecting multifocal steady-state visual evoked potentials associated with visual field stimulation is being developed as an objective test for identifying glaucoma-related visual function loss.

A review of glaucoma drugs in various clinical study phases reveals that at least seven new glaucoma drugs were in trials and two others were approved by the FDA in 2017. Many drugs that have progressed the most act on prostaglandin receptors, though some combine this with other mechanisms of action.

When customizing treatment plans for glaucoma patients, selective laser trabeculoplasty (SLT) can be as useful in diagnosis as it is in reducing IOP, explains Inder Paul Singh, MD, FEBOphth.

After decades of slow, but steady, progress in the advancement of glaucoma as a subspecialty, the last quarter century has seen tremendous innovation in this field.

The 2017 Charles D. Kelman Lecture touched on three main areas-from the teaching of the phaco technique during the early years of phaco to use of phaco in glaucoma patients to the introduction of phaco to surgeons in developing countries.

Persistent bleeding in a glaucoma patient with neovascular glaucoma after metastatic renal carcinoma requires a range of surgical methods to treat.

A prospective, observational study found that eyes with mild POAG could be differentiated from pre-perimetric glaucomatous eyes, which also could be differentiated from normal eyes using OCTA-derived retinal vessel density measurements.